EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Integrated transcriptomic analysis and RT-qPCR validation using FFPE patient tissues reveal the role of FOXQ1 and MCM10 in ovarian cancer

Dwi A. Suryandari, Luluk Yunaini, Khaerunissa Anbar Istiadi, Alfi Khatib, Fadilah Fadilah

Eurasian Journal of Medicine and Oncology · 2026-08-14 · 10 (5) · 025470488

DOI: 10.36922/ejmo025470488 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Ovarian cancer has a high mortality rate due to late diagnosis and limited availability of reliable molecular biomarkers. Integrated transcriptomic analysis may facilitate the identification of key regulatory genes involved in tumor progression. Objective: To identify and validate key regulatory genes associated with ovarian cancer progression through integrated transcriptomic analysis and experimental validation. Methods: Differential gene expression analysis was conducted using the GSE18520 microarray dataset to compare ovarian cancer tissues with normal ovarian epithelium. Genes with log2 fold change ≥ 1, and adjusted p-value < 0.05 were considered significant. Functional enrichment and protein–protein interaction (PPI) network analyses were performed to prioritize hub genes. FOXQ1 and MCM10 were selected for experimental validation using quantitative real-time polymerase chain reaction (RT-qPCR) in formalin-fixed paraffin-embedded (FFPE) ovarian cancer tissues. Relative expression levels were calculated using the 2⁻ΔΔCt method and normalized to GAPDH. Results: Transcriptomic analysis identified multiple differentially expressed genes associated with cell cycle regulation, DNA replication, and transcriptional control. FOXQ1 (log2 fold change = +5.00) and MCM10 (log2 fold change  = +2.74) were significantly upregulated and occupied central hub positions in the PPI network. RT-qPCR validation confirmed marked overexpression of FOXQ1 (45.3×) and MCM10 (11.3×) in FFPE ovarian cancer tissues. Conclusion: This integrated transcriptomic and experimental validation study identifies FOXQ1 and MCM10 as key regulators in ovarian cancer, highlighting their potential as biomarkers for disease progression.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →